|
Corporate Presentation |
|
Long-Term Safety and Efficacy of Seladelpar in Patients With Primary Biliary Cholangitis (PBC): 2-Year Results From a Long-Term Study |
|
Seladelpar reduces established liver and renal fibrosis in the non-obese diabetic inflammation and fibrosis (NIF) mouse model |
|
Efficacy and Safety of Seladelpar in Patients With Compensated Cirrhosis and Evidence of Portal Hypertension Due to Primary Biliary Cholangitis (PBC) |
|
Translational Studies of Seladelpar a PPAR-delta Agonist for the Treatment of NASH |
